IMGT Corporation Limited
KKRX:45657010,030.00
KRW
-1,770.00
(-15.00%)
ISIN
KR7456570001
Return %
Stock
S&P 500
1Y
-9.96
14.39
3Y
33.73
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Hak-Jong Lee
- Full Time Employees
- 27
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seongnam South Korea
- IPO Date
- Jul 19, 2023
- Website
- imgt.co.kr
- Similar Companies
- Business
- IMGT Corporation Limited is a South Korea-based biotechnology and medical device company that specializes in the development of image-guided therapy systems and ultrasound-mediated drug delivery platforms for oncology and central nervous system disorders. Founded in 2010 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, the company operates across the biopharmaceutical and medical equipment sectors, serving hospitals, academic research centers, clinical oncology institutions, and pharmaceutical partners. IMGT Corporation Limited integrates focused ultrasound hardware with advanced nanomedicine to enhance drug penetration and treatment precision, offering core products and services that include: focused ultrasound therapeutic systems designed for localized acoustic cavitation and non-invasive tumor ablation; ultrasound-responsive lipid and polymeric nanoparticle drug delivery carriers engineered to release chemotherapeutic payloads upon targeted acoustic stimulation; multifunctional ultrasound contrast agents and theranostic formulations for simultaneous molecular imaging and localized therapy; ultrasound-mediated blood-brain barrier opening platforms developed to enhance the delivery of therapeutics into the brain for neurological and glioblastoma applications; and image-guided medical navigation tools, including ultrasound-guided biopsy tracking and surgical localization systems. In recent developments, IMGT Corporation Limited listed its common stock on the KRX KONEX market under the ticker 456570 and initiated preparations for a transfer listing to the KOSDAQ market through specialized technology evaluation tracks; advanced clinical trials evaluating its proprietary therapeutic focused ultrasound device in combination with standard-of-care chemotherapy for patients with advanced pancreatic and solid tumors; secured venture and institutional financing to support clinical pipeline progression and regulatory compliance; and established strategic research collaborations with prominent university hospitals and biopharmaceutical developers to advance combination regimens utilizing ultrasound-triggered nanomedicines and immuno-oncology therapies.